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A B S T R A C T
Neurological melioidosis is a rare condition, as less than 30 cases have been reported in the last 50 years.
We present a case of neurological melioidosis, presenting with a cerebral abscess in a returning traveler
from an endemic area. While traveling in Cambodia on holiday, the patient was admitted to local hospital
for pneumonia. Her condition improved after antimicrobial treatment, and she returned to Norway
when discharged. The patient had several contacts with the health care system after returning to
Norway, due to recurrent fever and deterioration. Short-term antimicrobial treatment was given with
temporary improvement in her condition. Eventually she developed stroke-like symptoms, and a
cerebral abscess was found. Cultures from the abscess were positive for Burkholderia pseudomallei and
the treatment was adjusted accordingly.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Melioidosis is a disease caused by the pathogen Burkholderia
pseudomallei and the classical endemic regions are Southeast Asia
and territory of Northern Australia [1]. Outside these regions the
disease is uncommon, but is seen in returning travelers from
endemic areas. B. pseudomallei is a facultative Gram-negative
bacillus found in soil and surface water in the endemic regions.
Acquisition of the bacterium occurs mainly by inhalation of
contaminated dust or percutaneous inoculation of contaminated
soil and the majority of the cases occur in the rainy season
[1]. Traditional risk factors for more severe disease are excessive
alcohol consumption, diabetes, and chronic renal and lung disease
[2]. The microbe is also deﬁned as a Category B bioterrorism
agent due to its infectious potential and high virulence [1]. The
most common presentation of melioidosis is pneumonia, but a
variety of clinical presentations are described, including neurolog-
ical melioidosis. Accounting for approximately 4% of all cases of
melioidosis, neurological melioidosis has a high mortality rate of
approximately 25% [3].* Corresponding author at: Oslo University Hospital, Department of Micro-
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On holiday in Cambodia, during the rainy season, a 26-year-old
previously healthy woman and her boyfriend rented 4-wheel all-
terrain vehicles (ATVs) and went on a trip into more rural areas.
The woman rode behind her boyfriend in the trails, and his bike
made whirls of dust in front of her. Six days later she developed a
high fever and respiratory symptoms and was admitted to the local
hospital. Blood samples showed erythrocyte sedimentation rate
(ESR) 28 mm, C-reactive protein (CRP) 306 mg/L, white blood cell
(WBC) count 23  103/mm3, neutrophils 18  103/mm3, hemoglo-
bin 12.7 g/dL, normal platelets and creatinine. Initial chest X-ray
showed a patchy opacity in her left lung, and she was diagnosed
with pneumonia. Blood cultures, urine, sputum, and pleural ﬂuid
cultures were all negative. Her condition improved after 10 days of
ceftazidime intravenously, and she returned to Norway.
Two days after returning, she was admitted to hospital with
recurrent pneumonia. During this hospital stay, she reported a
tingling sensation and numbness in the skin on the left side of her
face and body. These symptoms were not further investigated. She
was dismissed from hospital after one week of ceftazidime
treatment.
Two days later she was admitted to Oslo University Hospital
with fever, headache, left sided hemiparesis and localized seizures
in the left side of her face and left arm. Blood samples showed ESR
28 mm, hemoglobin 12.4 g/dL, CRP 11.5 mg/L, WBC count
20  103/mm3 and neutrophils 17  103/mm3. Computer tomog-
raphy (CT) and magnetic resonance imaging (MRI) scans of thee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Initial MRI brain scan.
Fig. 2. MRI brain scan after 10 months of follow-up.
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diagnosed as a glioma or an abscess (Fig. 1). Supplementary CT
body scans did not reveal any other infection sites. Brain biopsy
and diagnostic abscess drainage was performed. From the biopsy
material a non-fermentative Gram-negative bacillus was isolated,
and given her history, B. pseudomallei was suspected. To avoid
laboratory-acquired infections the laboratory personnel were
informed of the possible contagious microbe and further labora-
tory work was done within Biosafety Level 3 facilities. Initial
identiﬁcation of the microbe was done from cultured colonies by
using matrix-assisted laser desorption ionization-time of ﬂight
mass spectrometry (MALDI-TOF MS). The results suggested B.
thailandiensis, a non-pathogenic species, genetically closely related
to B. pseudomallei. Finally 16 rRNA PCR gene sequencing from the
abscess material conﬁrmed B. pseudomallei.
Shortly after the brain biopsy, on ceftazidime treatment
(2 grams three times daily), the patient deteriorated. Susceptibility
testing of the B .pseudomallei isolate, however, showed no
resistance to ceftazidime which was increased to four times daily
and sulfamethoxazole/trimethoprim (SXT) was added with subse-
quent improvement. The patient, who weighed 52 kg, received
4 weeks of treatment with ceftazidime 2 g four times daily and
SXT (2400 mg/480 mg daily). Due to subsequent bone marrow
suppression and rash, SXT was switched to oral amoxicillin/
clavulanate (3500 mg/875 mg daily) and doxycycline (200 mg
daily) for a total of 6 months. After 12 months of follow-up no
relapse had occurred, MRI scans showed marked improvement
(Fig. 2) and the patient completely recovered without neurological
sequelae.
Discussion
To our knowledge, no previous cases of neurological melioidosis
from Cambodia have been published. Few clinicians haveencountered the condition in travelers returning from endemic
regions [4,5]. Only 2 previously reported cases of traditional
melioidosis in Norway have been published [6]. Diagnosing
neurological melioidosis, far from endemic regions, is challenging,
due to lack of clinical experience, low rate of detection and
diagnostic challenges. Our patient had no traditional risk factors,
except potentially exposure to B. pseudomallei while riding the ATV
motorbikes. Two Australian publications found that 25–42% of
their patients with neurological melioidosis had no risk factors
[7,8]. Neurological melioidosis might have a different risk proﬁle
than ordinary melioidosis, and may not trigger the clinical
suspicion of the disease. Culture of B. pseudomallei from any
clinical specimen remains the diagnostic gold standard. Cerebro-
spinal ﬂuid (CSF) has shown a low detection rate [8], and searching
for other sites of infection is essential [9]. In general, fast, accurate
and safe microbe identiﬁcation is always important, but especially
as B. pseudomallei and B. mallei, both are classiﬁed as Category B
bioterrorism agents [1]. All clinical and microbiological experience
with these microbes is useful, due to its effective bioterror
potential. Matrix-assisted laser desorption ionization-time of ﬂight
mass spectrometry (MALDI-TOF MS) has the potential of rapid and
reliable identiﬁcation of pathogens, including B. pseudomallei
[10]. The availability of a database containing the validated
reference spectra limited the possibility of accurate species
identiﬁcation in our case. 16 rRNA PCR gene sequencing was the
most accurate identiﬁcation method in our setting.
The pathogenesis of cerebral melioidosis has been debated. At
present, there is no evidence of speciﬁc CNS invasive strains
[7]. Our patient had no signs of sinusitis as a possible link to
neurological melioidosis, as seen in other cases [3].
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et al. [11], our patient had an inhalational melioidosis, with a
probable primary focus in the left lung and secondary dissemina-
tion to CNS. It has been suggested that macro abscess formation
can occur, particularly in untreated or insufﬁciently treated cases
and this feature carries a poor prognosis [12]. B. pseudomallei can
disseminate rapidly, and the initial delay in diagnosing and
adequately treating the condition may have contributed to the
development of neurological melioidosis in our patient.
The best antimicrobial treatment for cerebral melioidosis is still
being discussed. Currently recommended initial therapy is
intravenous ceftazidime or meropenem, alone or with SXT
[3,8,13]. After returning to Norway she received initial treatment
according to treatment recommendations with intravenous
ceftazidime and SXT for 4 weeks. However, the eradication
therapy consisted of amoxicillin 3.5 g/day and clavulanic acid
875 mg/day given in an eight hourly regime, combined with
doxycycline 200 mg daily for six months. The concentration of
amoxicillin–clavulanic acid in CSF is <10% relative to blood, which
falls below the MIC for B. pseudomallei. Accordingly, amoxicillin–
clavulanic acid is not recommended for eradication therapy when
CNS manifestations [14]. Pharmacokinetic and pharmacodynamic
studies in plasma concentration conclude that by oral eradication,
an eight hourly dosing interval of 1000 mg amoxicillin and 250 mg
clavulanic acid is sub-optimal [15], and a six hourly regimen
should be considered.
To conclude, this case report demonstrates a successful
outcome in a patient with neurological melioidosis, despite
challenges in diagnosing the disease and using eradication therapy
alternative to that recommended. It highlights the clinical and
diagnostic challenges encountered and shows the importance of
awareness in clinicians and laboratory personal of this disease in
non-endemic areas, in returning travelers or as a consequence of
bioterror.Conﬂict of interest
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